AMALGAMATED BANK - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 277 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.

Quarter-by-quarter ownership
AMALGAMATED BANK ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2024$474
+115.5%
6,922
+117.3%
0.00%
+100.0%
Q1 2024$220
-77.1%
3,186
-76.2%
0.00%
-75.0%
Q4 2023$959
+28.6%
13,394
-6.5%
0.01%
+33.3%
Q3 2023$746
-16.9%
14,327
+1.1%
0.01%
-14.3%
Q2 2023$898
+27.7%
14,175
+9.1%
0.01%
+16.7%
Q1 2023$703
-11.7%
12,988
-13.6%
0.01%
-14.3%
Q4 2022$796
-99.9%
15,036
+1.4%
0.01%0.0%
Q3 2022$690,000
-17.6%
14,823
+1.1%
0.01%
-12.5%
Q2 2022$837,000
+3.8%
14,662
+11.3%
0.01%
+33.3%
Q1 2022$806,000
-38.1%
13,172
-47.0%
0.01%
+20.0%
Q4 2021$1,302,000
+177.6%
24,876
+97.9%
0.01%
+25.0%
Q3 2021$469,000
-13.9%
12,573
-5.8%
0.00%0.0%
Q2 2021$545,000
+132.9%
13,346
+93.3%
0.00%
-55.6%
Q1 2021$234,000
-1.7%
6,905
-7.9%
0.01%0.0%
Q4 2020$238,000
-13.5%
7,496
-6.4%
0.01%
+80.0%
Q4 2019$275,0008,0090.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2023
NameSharesValueWeighting ↓
DCF Advisers, LLC 375,000$15,308,0005.42%
SILVERARC CAPITAL MANAGEMENT, LLC 113,258$4,623,0002.06%
Tri Locum Partners LP 150,783$6,155,0002.02%
COOPER/HAIMS ADVISORS, LLC 61,116$2,495,0001.64%
Vantage Consulting Group Inc 226,670$9,252,0001.61%
Nicholas Investment Partners, LP 598,261$24,421,0001.53%
Bellevue Group AG 3,609,919$147,357,0001.44%
GENERAL AMERICAN INVESTORS CO INC 350,804$14,320,0001.20%
Rhenman & Partners Asset Management AB 429,728$17,541,0001.19%
WASATCH ADVISORS LP 6,506,789$265,607,0001.08%
View complete list of INTRA CELLULAR THERAPIES INC shareholders